MIF and colitis: Interestingly, in a colitis-associated mice cancer model, Lpar2−/− showed a decrease in tumor incidence and in progression to colon adenocarcinomas by reducing proliferation and proinflammatory factors such as monocyte chemoattractant protein-1 (MCP-1) and macrophage migration inhibitory factor (MIF) [114].